FAAH and colitis: In contrast to the pathological role of the ECS in the liver and VAT (13, 18, 53), activation of CB1 or CB2 receptors (via exogenous agonists or FAAH inhibition) has been shown to reduce macroscopic damage scores of colonic inflammation and to attenuate the activation of T-cells and the infiltration of inflammatory cells in animal models of colitis (21, 22, 50, 51).